EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Time Course of Early Hematoma Expansion in Acute Spot-Sign Positive Intracerebral Hemorrhage: Prespecified Analysis of the SPOTLIGHT Randomized Clinical Trial

Fahad S Al-Ajlan iD, David J Gladstone, Dongbeom Song, Kevin E Thorpe iD, Rick H Swartz, Kenneth S Butcher iD, Martin Del Campo, Dar Dowlatshahi iD, Henrik Gensicke iD, Gloria Jooyoung Lee, Matthew L Flaherty iD, Michael D Hill iD und 3 weitere

Stroke · 2023-03 · 54 (3) · 715-721

DOI: 10.1161/strokeaha.121.038475 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Stroke, 2023-03. Verfasst von Fahad S Al-Ajlan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences (Neurology), King Faisal Specialist Hospital and Research Center, Alfaisal University, Riyadh, Saudi Arabia (F.S.A.-A.). Hauptthemen laut MEDLINE: Factor VIIa, Hemostatics. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the SPOTLIGHT trial (Spot Sign Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy), patients with a computed tomography (CT) angiography spot-sign positive acute intracerebral hemorrhage were randomized to rFVIIa (recombinant activated factor VIIa; 80 μg/kg) or placebo within 6 hours of onset, aiming to limit hematoma expansion. Administration of rFVIIa did not significantly reduce hematoma expansion. In this prespecified analysis, we aimed to investigate the impact of delays from baseline imaging to study drug administration on hematoma expansion.

Methods

Hematoma volumes were measured on the baseline CT, early post-dose CT, and 24 hours CT scans. Total hematoma volume (intracerebral hemorrhage+intraventricular hemorrhage) change between the 3 scans was calculated as an estimate of how much hematoma expansion occurred before and after studying drug administration.

Results

Of the 50 patients included in the trial, 44 had an early post-dose CT scan. Median time (interquartile range) from onset to baseline CT was 1.4 hours (1.2–2.6). Median time from baseline CT to study drug was 62.5 (55–80) minutes, and from study drug to early post-dose CT was 19 (14.5–30) minutes. Median (interquartile range) total hematoma volume increased from baseline CT to early post-dose CT by 10.0 mL (−0.7 to 18.5) in the rFVIIa arm and 5.4 mL (1.8–8.3) in the placebo arm ( P =0.96). Median volume change between the early post-dose CT and follow-up scan was 0.6 mL (−2.6 to 8.3) in the rFVIIa arm and 0.7 mL (−1.6 to 2.1) in the placebo arm ( P =0.98). Total hematoma volume decreased between the early post-dose CT and 24-hour scan in 44.2% of cases (rFVIIa 38.9% and placebo 48%). The adjusted hematoma growth in volume immediately post dose for FVIIa was 0.998 times that of placebo ([95% CI, 0.71–1.43]; P =0.99). The hourly growth in FFVIIa was 0.998 times that for placebo ([95% CI, 0.994–1.003]; P =0.50; Table 3).

Conclusions

In the SPOTLIGHT trial, the adjusted hematoma volume growth was not associated with Factor VIIa treatment. Most hematoma expansion occurred between the baseline CT and the early post-dose CT, limiting any potential treatment effect of hemostatic therapy. Future hemostatic trials must treat intracerebral hemorrhage patients earlier from onset, with minimal delay between baseline CT and drug administration. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01359202.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor VIIaHemostaticsHumansCerebral HemorrhageHematomaTomography, X-Ray Computed

Stichwörter der Autor:innen

activated factor VIIhematoma expansionintracerebral hemorrhagerFVIIastroketranexamic acid

Substanzen

Factor VIIaHemostatics

Autor:innen und Institutionen

  • Department of Neurosciences (Neurology), King Faisal Specialist Hospital and Research Center, Alfaisal University, Riyadh, Saudi Arabia (F.S.A.-A.).
  • Sunnybrook Research Institute, Hurvitz Brain Sciences Program and Department of Medicine, Sunnybrook Health Sciences Centre (D.J.G., R.H.S.).
  • Department of Medicine (Neurology), University of Toronto, Canada (D.J.G., R.H.S., M.D.C.).
  • Calgary Stroke Program, Department of Clinical Neurosciences, Department of Radiology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Canada (D.S., G.J.L., M.D.H., A.M.D.).
  • Applied Health Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Dalla Lana School of Public Health, University of Toronto, Canada (K.E.T.).
  • Prince of Wales Clinical School, University of New South Wales, Sydney, AustraliaDepartment of Medicine (Neurology), University of Alberta, Edmonton, Canada (K.S.B.).

ORCID-Profile: Fahad S Al-Ajlan, Kevin E Thorpe, Kenneth S Butcher, Dar Dowlatshahi, Henrik Gensicke, Matthew L Flaherty, Michael D Hill, Richard I Aviv, Andrew M Demchuk

Förderung

  • CIHR

Zitieren

APA

Al-Ajlan, F. S., Gladstone, D. J., Song, D., Thorpe, K. E., Swartz, R. H., Butcher, K. S., Del Campo, M., Dowlatshahi, D., Gensicke, H., Lee, G. J., Flaherty, M. L., Hill, M. D., Aviv, R. I., Demchuk, A. M., & SPOTLIGHT Investigators (2023). Time Course of Early Hematoma Expansion in Acute Spot-Sign Positive Intracerebral Hemorrhage: Prespecified Analysis of the SPOTLIGHT Randomized Clinical Trial. Stroke, 54(3), 715-721. https://doi.org/10.1161/strokeaha.121.038475

Vancouver

Al-Ajlan FS, Gladstone DJ, Song D, Thorpe KE, Swartz RH, Butcher KS, et al. Time Course of Early Hematoma Expansion in Acute Spot-Sign Positive Intracerebral Hemorrhage: Prespecified Analysis of the SPOTLIGHT Randomized Clinical Trial. Stroke. 2023;54(3):715-721. doi:10.1161/strokeaha.121.038475

BibTeX
@article{AlAjlan2023,
  author = {Al-Ajlan, Fahad S and Gladstone, David J and Song, Dongbeom and Thorpe, Kevin E and Swartz, Rick H and Butcher, Kenneth S and Del Campo, Martin and Dowlatshahi, Dar and Gensicke, Henrik and Lee, Gloria Jooyoung and Flaherty, Matthew L and Hill, Michael D and Aviv, Richard I and Demchuk, Andrew M and SPOTLIGHT Investigators, SPOTLIGHT Investigators},
  title = {Time Course of Early Hematoma Expansion in Acute Spot-Sign Positive Intracerebral Hemorrhage: Prespecified Analysis of the SPOTLIGHT Randomized Clinical Trial},
  journal = {Stroke},
  year = {2023},
  volume = {54},
  number = {3},
  pages = {715--721},
  doi = {10.1161/strokeaha.121.038475}
}
Kostenlos starten →